Azathioprine

Febuxostat is contraindicated in patients being treated with azathioprine. Concomitant administration could increase plasma concentrations resulting in severe toxicity.

Febuxostat is contraindicated with azathioprine. Concomitant use increases plasma concentrations of 6-mercaptopurine metabolite, resulting in severe toxicity.

Should not be used concomitantly with natalizumab due to potential increased risk of PML and other infections.

Should not be used concomitantly with natalizumab due to increased risk of PML and other infections in Crohn's disease patients.

Immunosuppressive drug with risk of added immunosuppression. Concomitant use with XELJANZ/XELJANZ XR is not recommended.

Concomitant use requires dose reduction of azathioprine as recommended in its prescribing information.

Allopurinol inhibits xanthine oxidase-mediated metabolism, increasing azathioprine exposure and risk of adverse effects. Reduce dose.

Use to control hypertension has been reported to induce anemia and severe leukopenia in patients on azathioprine.

Concurrent use may increase risk for blood disorders, bone marrow failure, and associated complications. Monitor blood tests including complete blood cell counts and platelet counts.

Drug affecting leukocyte production may lead to exaggerated leukopenia, especially in renal transplant recipients.

Increased risk of hepatotoxicity including liver necrosis with concomitant use.

Increased risk of blood disorders and bone marrow failure; monitor complete blood cell counts and platelet counts if concurrent use unavoidable.

Patients receiving concomitant therapy with methotrexate and azathioprine should be closely monitored for possible increased risk of hepatotoxicity.

Competition for purine metabolism; concomitant administration is not recommended.

Concurrent use may increase risk of blood dyscrasias, bone marrow failure, and associated complications. Monitor complete blood cell counts and platelet counts.

Concomitant use induces severe pancytopenia and increases risk of azathioprine-related myelotoxicity through interference with IMDH metabolic pathway.

Azathioprine added to basiliximab regimen with cyclosporine and corticosteroids; no dose adjustment necessary. Total body clearance of basiliximab reduced by average 22%.

Increased risk of hepatotoxicity including liver necrosis when used with cyclophosphamide.

Aminosalicylate derivative inhibits TPMT enzyme. Concomitant use should be done with caution.

Aminosalicylate derivative inhibits TPMT enzyme. Concomitant use should be done with caution.

Immunomodulator used concomitantly in approximately 30% of subjects with Crohn's disease and ulcerative colitis; did not appear to influence overall safety or efficacy.

Immunomodulator used concomitantly in approximately 30% of Crohn's disease and ulcerative colitis subjects. Use did not appear to influence overall safety or efficacy of ustekinumab.

Immunomodulator used concomitantly in approximately 30% of Crohn's disease and ulcerative colitis subjects. Use did not appear to influence overall safety or efficacy of ustekinumab.

Immunomodulator used concomitantly in approximately 30% of Crohn's disease and ulcerative colitis subjects; did not appear to influence overall safety or efficacy.

Used concomitantly in approximately 30% of Crohn's disease and ulcerative colitis subjects; did not appear to influence overall safety or efficacy.

Immunomodulator used concomitantly in approximately 30% of Crohn's disease and ulcerative colitis subjects; did not appear to influence overall safety or efficacy.

Immunomodulator used concomitantly in ~30% of CD/UC subjects; did not appear to influence overall safety or efficacy of ustekinumab.

Azathioprine may inhibit the anticoagulant effect of warfarin.

Administered concomitantly in clinical trials without evidence of clinically meaningful effect on belimumab pharmacokinetics.

Romiplostim may be used with azathioprine as part of medical ITP therapy combination.

Use with Other Agents Affecting Myelopoesis Drugs which may affect leukocyte production, including co-trimoxazole, may lead to exaggerated leukopenia, especially in renal transplant recipients.